首页 | 本学科首页   官方微博 | 高级检索  
     


Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study
Authors:A. Blauvelt  K. Reich  S. Mehlis  F. Vanaclocha  H. Sofen  W. Abramovits  Y. Zhao  I. Gilloteau  E. Davenport  N. Williams  A. Guana  S. Tyring
Affiliation:1. Oregon Medical Research Center, Portland, OR, USA;2. Dermatologikum Hamburg and SCIderm GmbH, Hamburg, Germany;3. NorthShore University Health System, Skokie, IL, USA;4. Dermatology Department, Hospital Universitario, Madrid, Spain;5. Department of Medicine (Dermatology) UCLA, Los Angeles, CA, USA;6. Baylor University Medical Center, Dallas, TX, USA;7. Formerly with Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;8. Novartis Pharma AG, Basel, Switzerland;9. RTI Health Solutions, Research Triangle Park, NC, USA;10. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;11. University of Texas Health Science Center for Clinical Studies, Houston, TX, USA
Abstract:
Keywords:
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号